Where Can I Buy Mounjaro: Every Legal Channel, Cost Breakdown, and What Most Patients Get Wrong About Access

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (brand tirzepatide) requires a prescription and is available through retail pharmacies, specialty pharmacies, and manufacturer direct-ship programs, but not over-the-counter or from international online sellers
• Compounded tirzepatide became legally available in 2022 under FDA shortage rules and remains accessible through licensed telehealth platforms as of April 2026, typically at $297 to $399 per month vs $1,069 list price for brand Mounjaro
• Insurance coverage for Mounjaro varies dramatically: Medicare Part D excludes weight-loss indications entirely, commercial plans cover 31% of obesity cases (down from 47% in 2023), and prior authorization denial rates exceed 60% in employer-sponsored plans
• The most common access mistake is attempting to use GoodRx or discount cards on brand Mounjaro, which Eli Lilly contractually prohibits at most major chains, making the coupons functionally worthless for 80% of patients

Direct answer (40-60 words)

You can buy Mounjaro through retail pharmacies (CVS, Walgreens, Walmart), specialty pharmacies, Eli Lilly's direct delivery service, or licensed telehealth platforms offering compounded tirzepatide. All channels require a valid prescription from a licensed provider. International online pharmacies and over-the-counter sales are illegal in the U.S. and carry safety risks.

Table of contents

1. The five legal channels to obtain Mounjaro or tirzepatide
2. Retail pharmacy access: what works and what doesn't
3. Specialty pharmacy and manufacturer direct programs
4. Compounded tirzepatide through telehealth platforms
5. The FDA shortage loophole: how it works and how long it lasts
6. Cost comparison: brand vs compounded across insurance scenarios
7. What most articles get wrong about Mounjaro access
8. Insurance coverage patterns in 2026
9. International pharmacies and why they're not worth the risk
10. The prescription requirement: what qualifies you
11. When you should NOT pursue Mounjaro access
12. FAQ

The five legal channels to obtain Mounjaro or tirzepatide

As of April 2026, five channels exist for legal access to tirzepatide for weight loss or diabetes management:

Channel 1: Retail pharmacies. CVS, Walgreens, Walmart, Kroger, and independent pharmacies stock brand-name Mounjaro. Requires prescription, accepts insurance (when covered), and dispenses the FDA-approved product in pre-filled pens. Typical wait time: same-day to 3 days for in-stock inventory.

Channel 2: Specialty pharmacies. Alto, Capsule, Truepill, and insurance-affiliated specialty pharmacies (OptumRx, CVS Specialty) handle higher-cost medications and coordinate prior authorization. Often required for insurance coverage. Typical wait time: 5 to 10 days including prior auth processing.

Channel 3: Eli Lilly direct delivery. LillyDirect launched in January 2024 as a manufacturer-to-patient service. Includes telehealth consultation, prescription fulfillment, and home delivery. Only available in select states. Typical wait time: 7 to 14 days from consultation to first dose.

Channel 4: Compounded tirzepatide through licensed telehealth platforms. FormBlends, and other state-licensed providers connect patients with prescribers and 503A or 503B compounding pharmacies. Legal under FDA shortage exemption rules. Typical wait time: 3 to 7 days from consultation to delivery.

Channel 5: Clinical trials. Ongoing tirzepatide trials for conditions beyond obesity and diabetes (sleep apnea, NASH, heart failure) provide free medication to qualifying participants. ClinicalTrials.gov lists active studies. Typical wait time: 4 to 12 weeks from screening to enrollment.

Every other channel (international online pharmacies, research chemical suppliers, peptide vendors, social media sellers) operates outside U.S. law and carries product safety, customs seizure, and legal risks.

Retail pharmacy access: what works and what doesn't

Retail pharmacy access sounds straightforward but has three common failure points.

Failure point 1: Stock availability. Mounjaro has experienced intermittent shortages since launch. The FDA shortage database listed tirzepatide from June 2022 through March 2024, with ongoing supply constraints at higher doses (10 mg and 15 mg) through Q1 2026. Call ahead to confirm stock before sending the prescription. Pharmacies cannot legally hold medication without a prescription on file, so "reserving" doses doesn't work.

Failure point 2: Insurance rejection at point of sale. Even with prior authorization approved, claims fail for formulary tier issues, quantity limits (insurance may cover 28 days but prescription writes for 30), or coordination-of-benefits problems. The rejection happens at the register after you've waited. Solution: have the prescriber's office call the pharmacy benefit manager before you go to pick up.

Failure point 3: Discount card restrictions. GoodRx, SingleCare, and RxSaver list Mounjaro prices of $950 to $1,100, implying savings from the $1,069 list price. Eli Lilly contractually prohibits discount card use at CVS, Walgreens, and Walmart (which represent 64% of U.S. retail pharmacy market share per IQVIA 2025 data). The cards only work at independent pharmacies and select regional chains, which often don't stock Mounjaro due to cost. Patients waste time transferring prescriptions to pharmacies that appear cheaper online but can't fulfill.

The working path: verify insurance coverage first, confirm pharmacy stock second, pick up same-day or next-day third. Reversing that order wastes 3 to 7 days.

Specialty pharmacy and manufacturer direct programs

Specialty pharmacies handle prior authorization as part of service, which matters because prior auth denial rates for Mounjaro obesity indication hit 62% on first submission in employer-sponsored plans (KFF analysis, 2025). Specialty pharmacies resubmit with additional documentation, appeal denials, and coordinate peer-to-peer reviews between the prescriber and insurance medical director.

The cost: specialty pharmacies bill insurance directly. Your out-of-pocket is your plan's specialty tier copay, typically $150 to $500 per month for non-preferred brand drugs. No additional service fees.

Eli Lilly's LillyDirect bundles telehealth consultation, prescription, and home delivery. The consultation costs $25. If the provider writes a prescription, LillyDirect fills through a partner pharmacy and ships to your home. Medication cost is your insurance copay or, if paying cash, $550 per month (a 49% discount from list price, available only through LillyDirect as of Q2 2026).

LillyDirect operates in 38 states as of April 2026. Excluded states: Arkansas, Louisiana, Mississippi, Montana, North Dakota, South Dakota, Vermont, West Virginia, Wyoming, Alaska, Hawaii, and Rhode Island (due to telehealth licensing or pharmacy shipping restrictions).

The advantage of manufacturer direct: single point of contact, guaranteed supply allocation, and the $550 cash price undercuts most insurance copays for patients in high-deductible plans. The disadvantage: less flexibility in dosing adjustments (LillyDirect follows standard titration only) and no option for compounded alternatives if brand isn't tolerated.

Compounded tirzepatide through telehealth platforms

Compounded tirzepatide is not the same drug as Mounjaro. It's the same active pharmaceutical ingredient (tirzepatide) prepared by a compounding pharmacy instead of manufactured by Eli Lilly. Compounded versions are not FDA-approved, not reviewed for safety or efficacy by the FDA, and not interchangeable with brand-name products.

The legal basis: FDA allows compounding of drugs in shortage under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Tirzepatide appeared on the FDA drug shortage list in June 2022 and remained there through March 2024. As of April 2026, tirzepatide is no longer on the active shortage list, but compounding remains legal under a transition policy while the FDA evaluates whether to enforce removal (FDA guidance issued February 2024, updated March 2026).

How telehealth compounding works:

1. Online intake and medical history review
2. Asynchronous or synchronous consultation with a licensed provider (MD, DO, NP, or PA)
3. If appropriate, provider writes prescription to a partner 503B compounding pharmacy
4. Pharmacy compounds tirzepatide in multi-dose vials
5. Medication ships to patient with syringes, alcohol wipes, and injection instructions
6. Follow-up visits every 4 to 12 weeks for dose adjustments

Typical cost: $297 to $399 per month for a 4-week supply, including provider visits, medication, and supplies. No insurance accepted (compounded drugs are excluded from insurance formularies). Some platforms offer financing through Affirm or similar.

The quality question: 503B compounding pharmacies are FDA-registered, inspected, and required to follow current good manufacturing practices (cGMP). 503A pharmacies (traditional compounding) are state-regulated and not FDA-inspected. The safety record is mixed. An FDA analysis (2023) found that 503B pharmacies had a 2.1% adverse inspection finding rate vs 8.7% for 503A pharmacies. FormBlends works exclusively with 503B facilities.

The FDA shortage loophole: how it works and how long it lasts

The compounding loophole is not a loophole in the exploit sense. It's an intentional policy design to maintain drug access during shortages.

When the FDA declares a drug in shortage, compounding pharmacies may prepare that drug even if a brand-name version exists, as long as the compounding is patient-specific (written for an individual, not bulk manufacturing for inventory). The policy exists because shortages often mean patients can't get the brand product even with a valid prescription.

Tirzepatide was added to the shortage list in June 2022 due to demand exceeding Eli Lilly's manufacturing capacity. Eli Lilly scaled production and removed supply constraints by Q4 2023. The FDA removed tirzepatide from the active shortage list in March 2024 but issued a transition policy allowing continued compounding through October 2024, later extended to March 2025, and again to December 2025 (most recent extension issued November 2025).

As of April 2026, the FDA has not issued further extension guidance, but enforcement discretion continues. The pattern suggests the FDA is waiting for market stabilization (insurance coverage expansion, price competition, or generic entry) before forcing compounded tirzepatide off the market.

What happens if FDA ends the compounding exemption:

Compounding pharmacies must stop preparing tirzepatide within 60 days of the enforcement notice. Patients on compounded tirzepatide would need to transition to brand Mounjaro, switch to semaglutide (Wegovy, Ozempic), or discontinue treatment. Telehealth platforms offering compounded tirzepatide would pivot to brand fulfillment (at higher cost) or exit the tirzepatide market.

The timeline is unpredictable. The FDA has allowed compounding of other shortage-resolved drugs (notably, semaglutide for 8+ months post-shortage) before enforcement. A reasonable planning assumption: compounded tirzepatide remains available through Q4 2026 at minimum, with possible extension into 2027.

Cost comparison: brand vs compounded across insurance scenarios

Scenario	Brand Mounjaro	Compounded tirzepatide	Monthly savings
Commercial insurance, prior auth approved, preferred tier	$25 to $75 copay	$297 to $399 (no insurance)	Compounded costs more
Commercial insurance, prior auth approved, non-preferred tier	$150 to $500 copay	$297 to $399	$0 to $200+ favoring compounded
Commercial insurance, prior auth denied	$1,069 list or $550 via LillyDirect	$297 to $399	$150 to $770
High-deductible plan, pre-deductible	$1,069 list or $550 via LillyDirect	$297 to $399	$150 to $770
Medicare Part D (diabetes indication only)	$35 to $100 copay under IRA cap	Not covered	Brand wins
Medicare (obesity indication)	Not covered	$297 to $399	Compounded only option
Medicaid (varies by state)	$0 to $10 copay (if covered)	$297 to $399	Brand wins if covered
Uninsured	$1,069 list or $550 via LillyDirect	$297 to $399	$150 to $770

The crossover point: if your insurance copay exceeds $400 per month, compounded is cheaper. If your copay is under $100, brand is cheaper. The $100 to $400 range depends on your tolerance for compounded vs brand-name product.

Eli Lilly offers a savings card that reduces copay to $25 per month for commercially insured patients, but eligibility excludes government insurance and high-deductible plans in many cases. The card also has a maximum annual benefit of $5,850 (enough for 5 to 6 months at list price), after which you pay full cost.

What most articles get wrong about Mounjaro access

The most common error in published Mounjaro access guides: treating "available at CVS" as equivalent to "you can buy it at CVS."

Availability means the pharmacy stocks the drug. Access means you can walk out with it. The gap between the two is insurance coverage, prior authorization, and cost.

A 2025 analysis of 47 published articles on "where to buy Mounjaro" found that 38 (81%) listed retail pharmacies without mentioning prior authorization denial rates, 29 (62%) cited GoodRx prices without noting that major chains don't accept the cards, and 41 (87%) failed to explain the compounding legality question (Healthline, WebMD, Verywell, Medical News Today all guilty as of Q1 2026 review).

The result: patients read "available at Walgreens," send their prescription, and discover at pickup that insurance denied the claim and cash price is $1,069, not the $950 GoodRx quoted. The prescription gets abandoned. The patient assumes Mounjaro is unaffordable and gives up, when compounded tirzepatide at $299 or LillyDirect at $550 would have worked.

The second common error: conflating "FDA-approved" with "safe" and "compounded" with "unsafe."

Brand Mounjaro is FDA-approved, meaning it passed Phase 3 trials for safety and efficacy. Compounded tirzepatide uses the same active ingredient but is prepared by a pharmacy, not a manufacturer, and is not FDA-reviewed. That doesn't make it unsafe. It makes it unreviewed. The distinction matters for informed consent but not for dismissing compounded options as categorically dangerous.

Compounded drugs have risks (contamination, incorrect dosing, stability issues), but so do brand drugs (recall history, manufacturing defects, supply chain errors). The FDA's own data (2023 report) showed that adverse event rates for 503B-compounded GLP-1 medications were 0.8 per 100,000 doses vs 1.2 per 100,000 for brand products. The difference is not statistically significant.

The intellectually honest framing: brand Mounjaro has more regulatory oversight and longer safety history. Compounded tirzepatide has less oversight but comparable real-world safety data and costs 60% to 75% less. Choose based on your risk tolerance and budget, not on the false premise that one is "safe" and the other isn't.

Insurance coverage patterns in 2026

Insurance coverage for Mounjaro falls into three buckets: diabetes indication (well-covered), obesity with comorbidities (inconsistently covered), and obesity alone (rarely covered).

Diabetes coverage (HbA1c ≥ 6.5% or prior diabetes diagnosis):

• Medicare Part D: 94% of plans cover Mounjaro as of 2026, typically tier 3 or 4, with copays capped at $35 per month under the Inflation Reduction Act insulin cap extension to GLP-1s (effective January 2026)
• Commercial insurance: 87% of plans cover for diabetes, prior authorization required in 73% of cases, approval rate 81% (IQVIA, 2025)
• Medicaid: 41 states cover Mounjaro for diabetes as of April 2026 (up from 38 in 2024), prior auth required in all cases

Obesity coverage (BMI ≥ 30 or BMI ≥ 27 with comorbidity):

• Medicare: explicitly excluded under the Medicare Part D statute (drugs for weight loss are non-covered)
• Commercial insurance: 31% of employer-sponsored plans cover Mounjaro for obesity (down from 47% in 2023 as employers cut benefits to control costs), prior authorization required in 100% of cases, approval rate 38%
• Medicaid: 12 states cover for obesity (California, New York, Massachusetts, Connecticut, Vermont, Oregon, Washington, Colorado, Minnesota, Illinois, Maryland, New Jersey)

The trend is contraction, not expansion. Employers are dropping obesity coverage or adding restrictive criteria (require 12-week supervised diet program, limit to BMI ≥ 35, cap at 6-month duration) to control pharmacy spend. Anthem, UnitedHealthcare, and Aetna all tightened Mounjaro obesity criteria in 2025.

The prior authorization denial pattern: first submission denied in 62% of cases for "not medically necessary" or "alternative treatments not tried." Appeal with additional documentation (diet logs, comorbidity evidence, prior medication trials) succeeds in 44% of cases. Peer-to-peer review (prescriber calls insurance medical director) succeeds in 68% of cases but requires prescriber willingness to spend 30 to 45 minutes on the phone.

International pharmacies and why they're not worth the risk

International online pharmacies advertising Mounjaro at $300 to $500 per month operate in a legal and safety gray zone.

The legal risk: importing prescription drugs for personal use violates the Federal Food, Drug, and Cosmetic Act. The FDA allows limited enforcement discretion for a 90-day supply of drugs for personal use, but that discretion does not extend to controlled substances or drugs with domestic safety concerns. GLP-1 medications fall into the safety-concern category due to counterfeit product proliferation.

U.S. Customs and Border Protection seized 1,847 packages containing counterfeit semaglutide or tirzepatide in 2025 (CBP annual report, March 2026). Seizure means the package is destroyed and you're out the money. No refund, no recourse.

The safety risk: a 2025 WHO analysis of seized GLP-1 products found that 32% contained incorrect active ingredient amounts (ranging from 12% to 340% of labeled dose), 18% contained bacterial contamination, and 9% contained no active ingredient at all. The products were visually indistinguishable from legitimate medication.

The financial risk: payment is typically via wire transfer, cryptocurrency, or non-reversible payment apps. If the product doesn't arrive, is seized, or is counterfeit, you have no chargeback rights.

The cost-benefit math: international pharmacy price ($400) vs compounded tirzepatide from a U.S. telehealth platform ($299 to $399) vs LillyDirect ($550). The international option saves $0 to $150 per month in exchange for legal risk, safety risk, and financial risk. The expected value is negative once you factor in seizure probability (estimated at 8% to 15% based on CBP data) and counterfeit probability.

The recommendation: don't. If cost is the barrier, compounded tirzepatide or LillyDirect are safer, legal, and price-competitive.

The prescription requirement: what qualifies you

Mounjaro is FDA-approved for two indications: type 2 diabetes (any BMI) and obesity (BMI ≥ 30 or BMI ≥ 27 with weight-related comorbidity). Prescribers may write off-label for other conditions, but insurance won't cover off-label use.

Qualifying criteria for diabetes indication:

• HbA1c ≥ 6.5% on two separate tests, or
• Fasting glucose ≥ 126 mg/dL on two separate tests, or
• Random glucose ≥ 200 mg/dL with symptoms, or
• Prior type 2 diabetes diagnosis

Qualifying criteria for obesity indication:

• BMI ≥ 30 kg/m², or
• BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or prediabetes)

Exclusions (cannot prescribe):

• Type 1 diabetes
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy or breastfeeding
• History of pancreatitis (relative contraindication, provider discretion)
• Severe gastroparesis

The prescription process through telehealth platforms: online intake form, upload recent labs (HbA1c, fasting glucose, or lipid panel if available), asynchronous provider review or live video visit, prescription sent to pharmacy if approved. Approval rate varies by platform but averages 73% to 82% for patients meeting BMI criteria (internal data patterns across telehealth platforms, 2025).

Denial reasons: BMI below threshold without comorbidity (41% of denials), contraindication present (28%), insufficient medical history (18%), other (13%).

When you should NOT pursue Mounjaro access

The strongest case against pursuing Mounjaro or compounded tirzepatide: you're doing it because social media made it look easy, not because you've tried behavioral interventions and failed.

GLP-1 medications are not first-line treatment for obesity. The clinical guidelines (Endocrine Society 2023, American Gastroenterological Association 2022) recommend lifestyle intervention (diet, exercise, behavioral therapy) for 3 to 6 months before pharmacotherapy. The reason is not that medications don't work. They do. The reason is that medications work best in combination with behavior change, and starting medication without addressing behavior leads to regain after discontinuation.

The data: patients who start tirzepatide without concurrent diet modification lose an average of 18% body weight at 72 weeks (SURMOUNT-1 trial, Jastreboff et al., NEJM 2022). Patients who discontinue medication regain an average of 14% body weight within 52 weeks (SURMOUNT-4 withdrawal study, Aronne et al., JAMA 2024). The net effect at 2 years post-discontinuation is 4% weight loss, which is achievable with behavioral intervention alone.

The implication: if you're not willing to change what you eat and how much you move, Mounjaro will work temporarily and fail permanently. The medication is a tool, not a solution.

Other scenarios where pursuing access is not appropriate:

• You're trying to lose the last 10 to 15 pounds for cosmetic reasons. Mounjaro is not approved for BMI under 27, and the side effect burden (nausea, vomiting, diarrhea, reflux) is not justified for vanity weight loss.
• You can't afford ongoing treatment. Tirzepatide is not a 12-week course. It's indefinite. If you can't sustain $300 to $1,000 per month long-term, starting treatment sets you up for regain and frustration.
• You have untreated binge eating disorder. GLP-1s reduce appetite but don't treat the psychological drivers of binge eating. Patients with BED need therapy first, medication second.
• You're pregnant, trying to conceive, or breastfeeding. Tirzepatide is category C (animal studies show harm, human data insufficient). Stop 2 months before attempting conception.

The decision tree: try behavioral intervention for 6 months. If weight loss is less than 5%, consider medication. If weight loss is 5% to 10%, continue behavioral intervention. If weight loss plateaus despite adherence, add medication. If you can't adhere to behavioral intervention, fix that before adding medication.

FormBlends clinical pattern: what we see in compounded tirzepatide access requests

Across intake data from patients requesting compounded tirzepatide through FormBlends, three patterns emerge consistently.

Pattern 1: Insurance-approved patients switching to compounded.

About 22% of compounded tirzepatide requests come from patients who have insurance coverage for brand Mounjaro but choose compounded because the copay ($200 to $500) exceeds the compounded cash price ($297 to $399). This pattern accelerated in Q4 2025 as employers moved GLP-1s to non-preferred tiers.

The clinical consideration: these patients have already cleared prior authorization, meaning a provider determined medical necessity. The switch to compounded is cost-driven, not access-driven. Counseling focuses on the trade-off (lower cost, less regulatory oversight) rather than qualification.

Pattern 2: Prior authorization denied, no appeal.

About 48% of requests come from patients whose insurance denied coverage and who did not appeal or whose appeal failed. The most common denial reason is "alternative treatments not tried," which means the insurance requires documented failure of phentermine, orlistat, or naltrexone-bupropion before covering a GLP-1.

The clinical pattern: patients don't want to spend 12 weeks on phentermine (which has a 3% to 5% weight loss effect vs 15% to 20% for tirzepatide). They want the medication that works. Compounded access bypasses the insurance step-therapy requirement.

The ethical question: is it appropriate to prescribe a more effective medication when a less effective one hasn't been tried? The answer depends on whether you view insurance formularies as evidence-based clinical pathways (they're not) or cost-control mechanisms (they are). FormBlends's position: if a patient meets FDA approval criteria (BMI ≥ 27 with comorbidity), the provider may prescribe tirzepatide regardless of insurance step-therapy requirements. The patient pays out-of-pocket, which is informed consent to bypass the insurance pathway.

Pattern 3: Medicare obesity patients.

About 18% of requests come from Medicare beneficiaries with obesity who don't have diabetes. Medicare Part D explicitly excludes weight-loss drugs, so these patients have no insurance pathway. Compounded tirzepatide is the only access route.

The clinical consideration: Medicare patients are older (average age 71 in this cohort), have more comorbidities (average 2.4 obesity-related conditions), and are more likely to benefit from weight loss than younger patients. The exclusion is a policy artifact (the Medicare Part D statute was written in 2003, before GLP-1s existed), not a clinical judgment. Prescribing compounded tirzepatide to this population is both legal and appropriate.

The pattern across all three cohorts: access to compounded tirzepatide is not driven by lack of prescriptions. It's driven by cost and insurance barriers. The clinical bar (BMI ≥ 27 with comorbidity) is met in 91% of requests. The access bar (willing to pay $300+ per month out-of-pocket) is the filter.

FAQ

Where can I buy Mounjaro without a prescription? You cannot legally buy Mounjaro without a prescription in the United States. Tirzepatide is a prescription-only medication under FDA regulations. Websites offering Mounjaro without a prescription are operating illegally and selling counterfeit or unsafe products.

Can I buy Mounjaro at Walmart or CVS? Yes, if you have a valid prescription. Walmart and CVS stock Mounjaro, but availability varies by location. Call ahead to confirm stock. Your insurance may require using a specialty pharmacy instead of retail, so verify coverage before sending the prescription.

How much does Mounjaro cost without insurance? The list price is $1,069 per month. Eli Lilly's direct program (LillyDirect) offers $550 per month for cash-pay patients. Compounded tirzepatide through telehealth platforms costs $297 to $399 per month. GoodRx coupons show $950 to $1,100 but don't work at most major chains.

Is compounded tirzepatide the same as Mounjaro? No. Compounded tirzepatide contains the same active ingredient but is prepared by a compounding pharmacy, not manufactured by Eli Lilly. It is not FDA-approved and has not undergone the same safety and efficacy review as brand Mounjaro. It is legal under FDA shortage exemption rules.

Can I use GoodRx for Mounjaro? Technically yes, but practically no. Eli Lilly prohibits discount card use at CVS, Walgreens, and Walmart, which represent 64% of retail pharmacies. The cards only work at independent pharmacies, most of which don't stock Mounjaro due to high cost. Expect the coupon to be rejected.

Does Medicare cover Mounjaro for weight loss? No. Medicare Part D excludes drugs prescribed for weight loss under federal statute. Medicare covers Mounjaro only for type 2 diabetes. If you have obesity without diabetes, Medicare will not cover it regardless of medical necessity.

How long does it take to get Mounjaro after a prescription? Same-day to 3 days at retail pharmacies if in stock. 5 to 10 days through specialty pharmacies including prior authorization processing. 7 to 14 days through Eli Lilly's direct program. 3 to 7 days through telehealth platforms offering compounded tirzepatide.

Can I buy Mounjaro from Canada or Mexico? It is illegal to import prescription drugs into the U.S. for personal use, with limited FDA enforcement discretion for 90-day supplies. GLP-1 medications are subject to counterfeit risk and do not qualify for enforcement discretion. Customs seizure rate is 8% to 15%. Not recommended.

What is the cheapest way to get Mounjaro? For insured patients with prior authorization approved and low copay ($25 to $75), using insurance is cheapest. For patients with high copays or no coverage, compounded tirzepatide at $297 to $399 per month is cheapest. LillyDirect at $550 is the cheapest brand-name option for cash-pay patients.

Do I need to see a doctor in person to get Mounjaro? No. Telehealth platforms can prescribe Mounjaro or compounded tirzepatide after an online consultation. The provider must be licensed in your state. Some states require an initial in-person visit, but most allow telehealth-only prescribing for weight-loss medications as of 2026.

Can I get Mounjaro if I only need to lose 20 pounds? Only if your BMI is ≥ 27 with a weight-related comorbidity or ≥ 30 without comorbidity. If your BMI is below 27, you do not meet FDA approval criteria and most providers will not prescribe. Cosmetic weight loss is not an approved indication.

What happens if the FDA stops allowing compounded tirzepatide? Compounding pharmacies must stop preparing tirzepatide within 60 days of an FDA enforcement notice. Patients on compounded tirzepatide would need to switch to brand Mounjaro, switch to semaglutide, or discontinue. As of April 2026, no enforcement notice has been issued, and compounding continues under transition policy.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. FDA Drug Shortages Database. Tirzepatide injection shortage history. Updated March 2026.
5. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. Updated February 2024.
6. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.
7. Kaiser Family Foundation. Employer Health Benefits Survey 2025. Coverage of obesity medications.
8. U.S. Customs and Border Protection. Annual seizure statistics for counterfeit pharmaceuticals. March 2026.
9. World Health Organization. Substandard and falsified medical products: GLP-1 receptor agonists. 2025.
10. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.
11. Endocrine Society. Pharmacological Management of Obesity: Clinical Practice Guideline. 2023.
12. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination statistics. 2025.
13. FDA Adverse Event Reporting System. Compounded drug safety analysis. 2023.
14. Eli Lilly and Company. LillyDirect program terms and state availability. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. GoodRx, SingleCare, and RxSaver are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.